Cartesian Therapeutics' lead asset, Descartes-08, demonstrated a 7.1-point MG-ADL reduction at 12 months in Phase 2b. Find ...

The Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for obinutuzumab for the treatment of systemic lupus erythematosus (SLE). Findings ...

The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application for Gazyva® ...

Roche RHHBY announced that the FDA has accepted its supplemental application for Gazyva/Gazyvaro (obinutuzumab) to treat ...

Promising early results regarding the use of litifilimab in patients with CLE were presented as part of a late-breaking session at the 2026 AAD Annual Meeting.

Objective Cardiovascular diseases are a leading cause of morbidity and mortality in SLE. In this target population, ...

Systemic lupus erythematosus (SLE) involves ongoing inflammation, tissue damage from immune complexes, and incomplete immune resolution. A key factor ...

Sixth paragraph, fifth sentence of release issued April 20, 2026 at 10 p.m. PT/April 21, 2026 at 1 a.m. ET, should read: In addition, treatment with Gazyva plus standard therapy, versus placebo plus ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License ...

Transaction will add pro-forma profitable revenue, enhance predictability of financial performance, expand market share, and accelerate the ...

Accurate measurement of HMGB-1, neopterin and sIL-2R supports reliable assessment of immune activation across clinical and ...

Women with systemic lupus erythematosus who receive immunosuppressive therapy show a higher prevalence of cervical lesions and cervical human papillomavirus infection than immunocompetent women.